Publications by authors named "Rioghna R Pittock"
Article Synopsis
- Treatment options for Alzheimer’s disease (AD) are mainly symptomatic, but recent approval of anti-β-amyloid antibodies like lecanemab and aducanumab offers new approaches for early-stage AD.
- * The study aimed to evaluate how well the clinical trial eligibility criteria for these treatments apply to participants from the Mayo Clinic Study of Aging, focusing on those with early AD.
- * Out of 237 participants, applying the lecanemab eligibility reduced this to only 19 eligible candidates, suggesting that strict criteria limit access, while relaxing the criteria could increase eligibility to 17.4% of those with mild cognitive impairment.*
